
Health Care · Life Sciences Tools & Services
$175.47
-1.95%
Vol: 5.1M
Friday, May 1, 2026
Danaher issued EUR 3 billion in senior notes on April 29 with net proceeds of EUR 2.98 billion to finance the Masimo $9.9B acquisition. Q1 2026 adjusted EPS of $2.06 beat expectations despite revenue miss at $5.95B (up 3.5% YoY). Management guides 3%-6% 2026 growth driven by bioprocessing, life sciences recovery, and diagnostics stabilization. Board approved $0.40/share quarterly dividend. Analyst consensus is Strong Buy with 12-month target of $241.69.
Danaher issued €3 billion in senior notes on April 29 to finance the Masimo acquisition, with net proceeds of approximately €2.98 billion. The acquisition addresses Danaher's strategy to strengthen its diagnostics portfolio with pulse oximeter technology. Mandatory redemption occurs if the deal does not close by mid-November 2026. Company reported Q1 EPS of $2.06, beating estimates of $1.94. Management expects 3-6% growth in 2026 driven by bioprocessing and diagnostics stabilization. The acquisition financing indicates management confidence in closing the deal and expanding the healthcare technology portfolio.
Danaher reported Q1 2026 adjusted EPS of $2.06, up 9.5% YoY, beating analyst estimates of $1.94. Revenues increased 3.5% to $6.0B with non-GAAP core revenue +0.5% YoY. Management raised the top end of 2026 adjusted EPS guidance by $0.05 to $8.35-$8.55, signaling confidence in growth. The company's $9.9B acquisition of pulse oximeter maker Masimo strengthens its diagnostics portfolio. 2026 outlook expects 3%-6% growth driven by bioprocessing, life sciences recovery, and diagnostics stabilization.
Danaher faces analyst headwinds with Goldman Sachs cutting its price target to $230 from $265 on April 16, while Jefferies and Wolfe Research also trimmed targets. The company announced a quarterly dividend of $0.40 per share, payable April 24. Q1 2026 earnings will be reported on April 21 at 8:00 a.m. ET. Pre-market trading at $196, up 2.61% overnight. Recent reports indicate Danaher is planning to acquire Masimo (pulse oximeter maker) for $9.9 billion to expand diagnostics portfolio.
Acquiring Masimo for ~$9.9B including debt. Q4 EPS $2.23 beat estimates. Q1 earnings April 21 with $1.94 EPS expected. Consensus Strong Buy $248.60 PT.
Danaher scheduled Q1 2026 earnings call for April 21, 2026. Announced regular quarterly dividend of $0.40/share (payable April 24). Masimo acquisition progressing; expected to strengthen diagnostics franchise. Analysts maintain Strong Buy with $264.05 price target (20.2% upside). Q4 2025 EPS beat: $2.23 vs $2.17 estimate.
Danaher will announce Q1 2026 results on April 21. Analysts expecting $1.94 EPS (+3.2% YoY). Declared quarterly dividend of $0.40/share payable April 24. Announced $9.9B acquisition of Masimo Corporation. Q4 2025 EPS was $2.23 beating $2.17 estimate. Evercore ISI maintains Outperform but lowered target from $254 to $225.
Danaher dropped after Q4 2025 results with mixed fundamentals. Board approved $0.40/share quarterly dividend payable April 24. Stock recovered 2.71% to $196.19 with analysts maintaining Strong Buy at $264.05 target (20.2% upside), though price targets cut amid cautious guidance.
Danaher scheduled Q1 2026 earnings call April 21 at 8am ET. Board approved quarterly dividend $0.40 payable April 24. $9.9 billion Masimo acquisition expected to close H2 2026. Beckman Coulter entered AI collaboration with Innovaccer.
Danaher announced a definitive agreement to acquire Masimo Corporation for approximately $9.9 billion in cash, with close expected in H2 2026. CEO Rainer Blair projected 2026 revenue growth of 3%-6% with 100-basis-point operating margin expansion. Q4 2025 net earnings reached $1.2 billion ($1.66 per share) with full-year earnings of $3.6 billion ($5.03 per share). The company declared a regular quarterly dividend of $0.40 per share payable April 24. Q1 2026 earnings call is scheduled for April 21, 2026 at 8:00 a.m. ET.
DHR agreed to acquire Masimo at $180/share ($9.9B EV), expected close H2 2026. Masimo projected $530M+ EBITDA in 2027 with $125M+ cost synergies. FY2026 guidance: core revenue +3-6%, adjusted EPS $8.35-8.50. Q1 earnings April 21.
Danaher entered definitive agreement to acquire Masimo in nearly $10 billion deal. Q4 2025 sales of $6.84 billion beat consensus at $6.81 billion (up 4.5% YoY). Operating cash flow of $2.1 billion and free cash flow of $1.8 billion. Subsidiaries launched innovations. Board approved $0.40/share quarterly dividend payable April 24. 16 analysts rate Strong Buy with 12-month target of $250.56.
Danaher will host its first quarter 2026 earnings conference call on April 21, 2026. The company declared a $0.40 quarterly dividend payable April 24, 2026. Stock performance has been weak with 19.7% decline in 2026, reflecting concerns about the $9.9 billion Masimo acquisition and uncertainty around bioprocessing growth. Management has guided for low-single-digit core revenue growth in Q1. Analysts maintain consensus $239 price target.
Danaher Q4 sales $6.84B up 4.5% YoY beating consensus. EPS $2.23 exceeded $2.17 guidance. Acquiring Masimo for $9.9B closing H2 2026. Quarterly dividend $0.40. Stock down 20% YTD. 16 analysts Strong Buy with $250.56 target.
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| TMOTHERMO | $469.56 | -1.96% | -1.9% | 17.5x | 0.97 | $178.0B |
| DHRDANAHER | $175.47 | -1.95% | -6.9% | 19.7x | 0.99 | $126.7B |
| AAGILENT | $114.69 | -0.74% | +0.6% | 17.6x | 1.30 | $32.7B |
| WATWATERS | $306.56 | -0.86% | +1.7% | 18.9x | 1.20 | $30.4B |
| IQVIQVIA | $157.04 | -0.84% | -7.2% | 11.3x | 1.39 | $26.6B |
| MTDMETTLER | $1,269.64 | -0.55% | +0.8% | 24.9x | 1.44 | $25.8B |
Price below 200d MA — bearish structure.